Skip to main content

PPI Plaintiffs Request Judge to Club 300 Individuals Cases

PPI Plaintiffs Request Judge to Club 300 Individuals Cases

PPI Plaintiffs Request Judge to Club 300 Individuals Cases

Introduction

Gauging filing Short Form Complaint would not suffice to handle the wave of expected PPI lawsuits, Co-Lead Counsel for the plaintiffs filed a proposed case management order (PDF), requesting temporary clubbing of at least 300 plaintiffs living in the same state on one complaint. Though the defendants have opposed this motion, the plaintiffs strongly feel it would allow the filing of a large number of claims before the statute of limitations date expire at the same time save capital and resource allocation.

The Proton Pump Inhibitor lawsuit defendants, AstraZeneca Pharmaceuticals LP, Procter & Gamble Co., McKesson Corp., Takeda Pharmaceuticals USA Inc., Novartis Pharmaceuticals Corp., Pfizer Inc., and Pfizer subsidiary Wyeth, are facing a growing number of lawsuits. The drugs in question include Nexium, Prilosec, Prevacid, Protonix, and others. The plaintiffs allege that PPIs cause kidney injuries including acute interstitial nephritis, chronic kidney disease (CKD), and end-stage renal disease. Each allegation holds the drug manufacturers responsible for withholding information about the risks associated with the long-term use of the acid-reflux medications. In August 2017, the PPI lawsuits were centralized in the District of New Jersey before Judge Claire C. Cecchi for coordinated pretrial proceedings under MDL No. 2789 (In Re:  Proton-Pump Inhibitor Products Liability Litigation [No.II]).

In January, Judge Cecchi’s authorized the direct filing of future lawsuits in the MDL to avoid the delays associated with transferring claims from various district courts nationwide and standardize allegations raised in each case. Following this decision, the plaintiffs had two weeks to file a Master Complaint to outline all of the allegations against the manufacturers. Filing a Short Form Complaint was then allowed for individual plaintiffs giving the flexibility to adopt certain claims against the manufacturers applicable when initiating their case.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Teen E-cigarette Use Hits 10-Year Low

Categories: E-Cigarette: JUUL

Federal officials report a significant decline in teen vaping rates in the U.S., with about half a million fewer middle and high school…

Baltimore, Walgreens Reach Opioid Settlement Totaling $402.5m

Categories: Opioids

The City of Baltimore has reached a settlement with Walgreens over its involvement in the opioid crisis, marking the…

Drug Distributors Reach $300M Opioid Settlement

Categories: Opioids

The three largest U.S. drug distributors—McKesson Corp, Cencora Inc, and Cardinal Health Inc—have agreed to pay $300 million to settle claims by health insurers and benefit plans over their role in fueling the U.S.…

Labor Day Litigation Bonanza!     
Free Trials + 15% Discount!